ABSTRACT
Background In the post-pandemic period, COVID-19 continues to cause significant numbers of hospitalisations and deaths. We describe this burden and compare it to the burden of influenza in the first two post-pandemic years in Denmark.
Methods A cohort study including residents in Denmark from May 16, 2022, to June 7, 2024. Data were obtained from national registries, including information on Polymerase chain reaction (PCR) test-positive COVID-19 and influenza admissions, mortality within 30 days of admission, sex, age, COVID-19 and influenza vaccination, comorbidity, and living in long-term care facility for elderly. Negative binomial regression was used to estimate adjusted incidence rate ratios (aIRRs) to compare rates of admissions between COVID-19 and influenza. To assess severity of COVID-19 among hospitalized patients, we used Cox proportional hazard models to estimate adjusted hazard ratios (aHR) of 30-day mortality between COVID-19 and influenza.
Results Among 5,899,170 individuals, admissions with COVID-19 (n=24,687) were more frequent than admissions with influenza (n=8,682; aIRR 2.01, 95%CI 1.37-2.95), in particular during the first year (p=0.01), in the summer (p<0.001) and among people above 65 years of age (p<0.001). The number of deaths were also higher (COVID-19, n=2,393; influenza, n=522). Among patients, the risk of mortality of COVID-19 was higher than influenza in the 12-30 days following admission (0-11 days, aHR 1.08, 95%CI 0.94-1.25; 12-30 days, aHR 1.50, 95%CI 1.21-1.84), in particular among non-vaccinated for both COVID-19 and influenza (aHR 1.81, 95%CI 1.25-2.62), while it was similar to influenza among patients without comorbidities (aHR 1.07, 95%CI 0.63-1.80).
Conclusion COVID-19 represented a greater disease burden than influenza, with more hospitalisations and deaths, and more severe disease primarily among non-vaccinated and comorbid patients. These results highlight the continued need for attention and public health efforts to mitigate the impact of SARS-CoV-2.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was conducted as part of the Danish COVID-19 surveillance with governmental financial support.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was conducted as part of Statens Serum Institutes governmental duties as National Public Health Agency. According to Danish law, ethical approval or individual consent is exempt for anonymised aggregated register-based studies, such as the present. Due to the nature of this research, there was no direct involvement of patients or members of the public in the design or reporting of this study. Therefore, no approval from an ethics committee is required. The study is fully compliant with all legal and ethical requirements and there are no further processes available regarding such studies including IRBs. The IRB Datatilsynet waived ethical approval for this work as described above.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
Aggregated admission and mortality data are available for download from dashboards at Statens Serum Institut (www.ssi.dk). De-identified individual-level data are available for research upon reasonable request to Statens Serum Institut and the Danish Health Data Authority and within the framework of the Danish data protection legislation and any required permission from relevant authorities. Applications should be submitted to Forskerservice (https://sundhedsdatastyrelsen.dk/da/forskerservice) where they will be reviewed on the basis of relevance and scientific merit. Data are available now, with no defined end date.
